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Abstract
Despite the introduction of family planning services in most areas of the world, failures 
of contraceptive use often lead to unplanned pregnancies. These women often resort to 
unsafe methods to end their pregnancies, which contributes to the fourth leading cause 
of maternal mortality worldwide. Demographic variables that may affect the intention to 
discontinue the pregnancies would be demonstrated. Pros and cons of different types of 
induced abortions would be presented and discussed. Programs integrating counseling 
for women after failed family planning for future comprehensive reproductive health 
care will be shown. The gap between women’s reproductive desire to avoid pregnancy 
and altitude of contraceptive use may contribute to the prevalence of unintended preg-
nancy. Age, race/ethnicity, marital status, and socioeconomic characteristics should be 
considered in counseling women after failed family planning. Expanding the program 
that offers integrated abortion training would prepare more physicians to provide com-
prehensive care for family planning.
Keywords: unintended pregnancy, induced abortion, use of contraception
1. Introduction
It was estimated that 7.9% (95% UI 4.7–13.2) of all maternal deaths were due to abortion by a 
global systemic analysis conducted by the World Health Organization (WHO) [1]. Although 
it is lower than that by the previous report, i.e., up to 13% [2], abortion-related deaths remain 
the fourth leading cause of maternal mortality after hemorrhage, hypertensive disorders, and 
sepsis (Table 1). Moreover, as deaths consequent to unsafe abortion have decreased in recent 
years, the focus is shifting toward adverse outcomes associated with abortion [3]. It is esti-
mated that 7 million women were treated for complications from unsafe pregnancy termina-
tion in 2012 [4]. It is imperative that patients and families have access to the full spectrum 
of reproductive care options, including contraception method, pregnancy termination, and 
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Abortion Embolism Hemorrhage Hypertension Sepsis Other direct causes Indirect cause
N % (95% 
UI)
N % (95% UI) N % (95% UI) N % (95% UI) N % (95% UI) N % (95% UI) N % (95% UI)
Worldwide 193,000 7.9% 
(4.7–13.2)
78,000 3.2% 
(1.8–5.5)
661,000 27.1% 
(19.9–36.2)
343,000 27.1% 
(19.9–36.2)
261,000 10.7% 
(5.9–18.6)
235,000 9.6% 
(6.5–14.3)
672,000 27.5% 
(19.7–37.5)
Developed 
regions
1100 7.5% 
(5.7–11.6)
2000 13.8% 
(10.1–22.0)
2400 16.3% 
(11.1–24.6)
1900 12.9% 
(10.0–16.8)
690 4.7% 
(2.4–11.1)
2900 20.0% 
(16.6–27.5)
3600 24.7% 
(19.5–33.9)
Developing 
regions
192,000 7.9% 
(4.7–13.2)
76,000 3.1% 
(1.7–5.4)
659,000 27.1% 
(19.9–36.4)
341,000 14.0% 
(11.1–17.4)
260,000 10.7% 
(5.9–18.7)
232,000 9.6% 
(6.4–14.3)
668 27.5% 
(19·7–37.6)
1. Data shown are the estimated proportion of cause of death (%) with 95% uncertainty interval (95% UI); 2. Revised from Say et al. [1].
Table 1. Distribution of causes of deaths by millennium development goal regions.
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postabortion care. The provision of family planning policy is thus important in the women’s 
reproductive care to reduce the morbidity and mortality.
2. Unintended pregnancy after the use of contraception
The term “family planning” has been used synonymously with contraceptive practice. In this 
review, we focus on interventions for failed contraceptive behavior or methods and address 
unsafe abortion as a preventable outcome.
2.1. Unintended pregnancy
Ineffective contraceptive use contributes to unintended pregnancy. In many Eastern European 
and South Asian countries, two-thirds of abortions are estimated due to contraceptive failure, 
mostly from traditional method use, and one-third are due to unmet need for contraception 
[2, 3]. In developed countries, it has been reported that most abortions occur as a result of 
contraceptive failure, and a small proportion are due to nonuse of contraception [5]. Based on 
the data of the National Survey of Family Growth in the United States, the overall failure rate 
for reversible methods declined from 12% in 2002 to 10% in 2006–2010. Long-acting reversible 
contraceptives (the IUD and the implant) had the lowest failure rates (1%) and oral pills with 
the modest failure rate (6%), while condoms and withdrawal carried the highest probabilities 
of failure (13% and 20%, respectively) [6].
Unintended pregnancies unnecessarily expose women to the risks associated with pregnancy, 
unsafe abortion, and childbirth, thereby contributing to maternal mortality and morbidity. It 
has been estimated that 250,000 maternal deaths could have been prevented by contraception 
and an additional 30% of maternal deaths avoided by fulfillment of the unmet need for con-
traception in 2008 [7]. A reduction in the number of unintended pregnancies is the greatest 
health benefit of contraception.
2.2. Impact of unsafe abortion
The World Health Organization defines unsafe abortion as “a procedure for terminating a 
pregnancy that is performed by an individual lacking the necessary skills, or in an environ-
ment that does not conform to minimal medical standards, or both” [4]. Unsafe abortions and 
abortion complications as well as the demand for postabortion care also vary remarkably by 
geographic region. In many low- and middle-income countries (LMIC), abortion is illegal or 
highly restricted, leading some women to seek unsafe abortions. About 7 million women are 
treated for complications from unsafe abortion procedures annually in LMICs [8]. Two stud-
ies indicate that at least 8% of maternal mortality is due to unsafe abortion and the contribu-
tion of abortion may be as high as 18% of these deaths [1, 9]. Factors that increase morbidity 
and mortality of unsafe abortion include lack of provider skill, poor technique, unsanitary 
conditions for performing the procedure, lack of appropriate equipment, use of toxic sub-
stances, poor maternal health, increasing gestational age, and lack of access to postabortion 
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care [10]. Prevention of unsafe abortion is crucial and requires a multipronged approach 
including improved access to and accessibility to safe abortion procedures and provision of 
high-quality postabortion medical care [9, 10].
3. Induced abortion
3.1. Option counseling and consent
Counseling women who seek abortions is an essential component of abortion care. Some 
women may be uncertain or lack of emotional support needed before making their decision 
[11–13]. It is essential to obtain a complete medical history before the procedure. The risk of 
providing a procedure in the setting of an uncontrolled medical condition should be weighed 
against the risk of delaying the procedure, since abortion complications increase with gesta-
tional age [14]. Dating of the pregnancy can be calculated by a last menstrual period that cor-
relates with the uterine size on bimanual examination or by ultrasound. If the last menstrual 
period is discordant from the clinical examination, uterine fibroids are present, or if the physi-
cal examination is limited by obesity, ultrasound examination is useful to confirm gestational 
age. Ultrasonography can also help identify ectopic pregnancy or uterine anomalies before 
induced abortion.
3.2. Surgical versus medical for induced abortion
Medical and surgical methods are available for both first- and second-trimester abortions 
(Table 2). Medical abortion is generally chosen for early pregnancy, e.g., those less than 
7 weeks of gestation. Vacuum aspiration is appropriate for women presenting between 7 
and 14 weeks of gestation, although some doctors may offer medical abortion for pregnancy 
above 12 weeks. Three methods may be considered for second-trimester pregnancy termina-
tion: dilatation and evacuation, administration of systemic abortifacients, and intrauterine 
instillation of abortifacients [15].
To avoid anesthesia and surgery, some women prefer medical (drug-induced) abortion. 
However, medical abortion is associated with greater extent of pain, bleeding, and discom-
fort after the procedure, and more side effects in general than surgical abortion [14–16]. In 
First trimester Second trimester
Medical 
abortion
Combined mifepristone with prostaglandin 
regimens or prostaglandin-only regimens
Dilation and curettage (D&C)
Surgical 
abortion
Vacuum aspiration (manual or electric)
Dilation and evacuation (D&C)
Administration of systemic abortifacients (e.g., 
mifepristone and prostaglandins)
Intrauterine instillation of abortifacients (e.g., 
hypertonic saline, prostaglandin F2-alpha)
Table 2. Summary of methods of termination of pregnancy in the first and second trimesters.
Family Planning172
comparison to surgical abortion, first-trimester medical abortion is more painful, less effec-
tive, less acceptable, and associated with more negative experiences and complications after 
the medications [17]. In the second trimester, surgical abortion is as effective as medical 
 abortion [18].
A systematic literature review assessed the main reasons for women in early pregnancy to 
choose medical or surgical abortion [19]. Women opted for medical abortion because they 
thought the method being “more natural,” wished to have abortion in one’s home, and fear 
of complications. Women selecting surgical abortion viewed the process being quicker and 
safer, lesser pain, and bleeding. Women made decisions based mainly on rational informa-
tion from professionals, also on emotions, and especially fears. Support techniques for an 
informed consent are especially needed [19].
3.3. Surgical termination
Surgical approach is the long-standing standard for safe induced abortion through either 
dilation and curettage (D&C) or vacuum aspiration (VA) [14]. Various methods of pain 
control for surgical abortion were used: paracervical block, oral medications (nonsteroidal 
anti-inflammatory drugs, anxiolytics, opiates) with cervical block, intravenous (IV) mild 
to moderate sedation, and general anesthesia. The most effective pain control during first- 
trimester abortion has not been proposed, but most women reported lesser pain when given 
IV sedation [20].
3.3.1. Dilation and curettage (D&C)
Cervical dilation is generally needed before surgical intervention. Cervical dilation is gener-
ally needed before surgical curettage. As a general rule, the cervix is dilated to the width in 
millimeter equal to the gestational age in weeks. For example, the cervix is dilated to 7 mm for 
a 7-week gestation. Serial Hegar’s dilators were inserted until an appropriately sized curette 
can be introduced safely without a force to avoid cervix laceration (which would create a 
false passage into the cervix and risk excessive bleeding and severe uterine perforation). The 
curette is then used to gently scrape the uterine wall and remove the tissue in the uterus, 
which is examined to ensure the procedure is complete.
If there is difficulty with dilation, try slowly twisting the dilator to find the pathway through 
the cervix. An OS Finder or uterine sound can also be used for this purpose. The cervical canal 
and uterus can also be visualized with ultrasound guidance, allowing direct visualization of 
the dilator in the cervix. Cervical ripening agents, such as osmotic dilators or misoprostol, can 
help soften the cervix and ease dilation. For early gestations when dilation is difficult, con-
sider delaying the procedure for cervical preparation or offering a medical abortion instead.
3.3.2. Vacuum aspiration (VA)
Instead of sharp curettage, first-trimester surgical abortion can be performed by using suction 
to remove retained products of conception through the cervix. Manual vacuum aspiration 
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(MVA) uses a manual vacuum syringe and cannula, and electric vacuum aspiration (EVA) 
uses an electric pump. In both methods, the pump mechanism creates a vacuum that empties 
the uterus. Although there are no clear gestational age limits for MVA use, most providers 
will use it up until 8 to 10 weeks of gestation because it may need to be emptied multiple 
times during a procedure. The EVA machine should be powered on to create suction after the 
cannula is inserted into the uterus [14].
For patients with a tortuous or angulated cervix/uterus, consider ultrasound guidance to min-
imize the risk of perforation. If there is difficulty in placing the cannula after dilation because 
of curvature of the cervix/uterus, a sterile sound may be placed, and the cannula is inserted 
over the sound. The sound is then removed, and the vacuum aspirator is attached.
In 2010, a Cochrane review found that VA was safer, quicker, and less painful than sharp 
metal curettage and also led to less blood loss. However, they were similar in the incidence of 
sepsis post procedure, uterine perforation, or the need for re-evacuation [21]. MVA and EVA 
do not appear to differ substantially in efficacy [22]. VA can be performed in the absence of 
a fully equipped facility and at secondary health facilities, with or without electricity, and 
without the capacity for general anesthesia. It is suitable for low-income settings because it is 
more accessible and reduces the consequences of blood loss and worsening infection associ-
ated with transportation to tertiary health facilities [22].
3.3.3. Complications and management
First-trimester abortion is safe with 0.6 deaths per 100,000 abortions, while childbirth has 14 
times the risk, with 8.8 deaths per 100,000 live births [23]. Overall, less than 1% of women have 
major complications, and only <0.5% of women will have complications requiring hospital-
ization [23]. Nonetheless, alertness for complications and subsequent timely management are 
essential in providing safe abortions. There is a wide variation across studies in the definition 
of complications that required interventions [24]. The following complications were mostly 
reported in the literatures.
3.3.3.1. Hemorrhage
Hemorrhage as excessive bleeding requiring transfusion, hospital admission, or greater than 
500 mL of blood loss occurs in less than 1% of terminations [25]. Hysterectomy for severe 
hemorrhage is performed in 1.4 per 10,000 abortions of any gestational age. The risk factors 
for hemorrhage are provider inexperience, increasing gestational age, advanced maternal 
age, increased parity, prior cesarean section or uterine scar, fibroids, and a history of obstetric 
hemorrhage and gestational age. The causes of hemorrhage include atony, abnormal placen-
tation, cervical laceration, perforation, coagulopathy, and retained products of conception. 
Oxytocin given routinely during a first-trimester abortion does not decrease blood loss [25].
3.3.3.2. Cervical lacerations
The incidence of cervical laceration is approximately 2 per 1000 procedures [26]. Risk factors 
for cervical laceration are nulliparity, surgical inexperience, and inadequate dilation. Bleeding 
from cervical lacerations can be managed with direct pressure or cautery to the bleeding site and 
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suturing in cases with large laceration. If there is excessive bleeding or bleeding that continues 
despite repair, one should be concerned for a high laceration with possible uterine artery involve-
ment. High lacerations may require repair by laparotomy or laparoscopy. An important long-term 
consequence of cervical injury during dilation and curettage is cervical incompetence leading to 
subsequent late miscarriage, premature rupture of the membranes, or preterm birth [14, 16, 24].
3.3.3.3. Uterine perforation
Uterine perforation occurs in approximately 0.1–3.0 in 1000 procedures [26]. Perforations gen-
erally occur at the fundus and are more likely to cause complications if they occur after the 
first trimester. The instrument penetrates the uterus most likely the suction cannula, followed 
by a dilator and then a curette [27]. Instruments passing further than expected with little 
resistance or loss of a gritty sensation may suggest perforation. If a perforation is suspected 
and there is minimal blood loss and no concern for bowel involvement, patients can be moni-
tored for 2–4 h in the clinic. Patients with perforations with hemorrhage, concern for bowel 
involvement, or injury to other surrounding structures should be transferred to the hospital 
for laparoscopy or laparotomy [25].
3.3.3.4. Incomplete abortion
The clinical presentation of retained products of conception (RPOC) may include irregular 
uterine bleeding, pelvic pain, uterine tenderness, and fever. The ultrasound findings indica-
tive of RPOC are a hyperechoic endometrial thickness combined with abundant low-resistance 
flow in the myometrium or just beneath the endometrium. Using ultrasound for diagnosis of 
RPOC can be challenging because the ultrasound findings of asymptomatic and symptomatic 
women can be quite similar after abortion [28].
Repeat curettage, suction evacuation, removal by clamp ring, or hysteroscopic resection can 
be employed [29]. Hysteroscopic excision allows the retained placental products to be excised 
under direct vision and possibly leads to fewer uterine adhesions and incomplete evacua-
tion [29]. Women preferring to avoid surgical intervention can be treated with misoprostol in 
order to induce uterine contractions. Complete evacuation rates after taking misoprostol were 
varied in different routes of administration or doses or both [30]. Though there is insufficient 
evidence to draw firm conclusion, combination of progesterone receptor modulator mifepris-
tone with misoprostol could improve the evacuation rate [31].
3.3.3.5. Infections
Postabortion infections occur in less than 1% of procedures and are decreased with preopera-
tive doxycycline prophylaxis [32]. Infections usually occur days after the procedure is usually 
diagnosed in the presence of fever, pain, pelvic tenderness, and leukocytosis. Women should 
be evaluated for possible RPOC and re-aspirated if necessary. Without prompt treatment, the 
infection can spread to the uterus and pelvis. Further spread may lead to systemic infection 
presenting as bacteremia, sepsis, or septic shock [33]. The organisms involved are usually 
common vaginal bacteria. However, clinicians should be alert to potentially lethal infection 
by bacteria that produce toxins, such as Staphylococcus aureus, that may be resistant to some 
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penicillin: Clostridium perfringens and Clostridium sordellii; group A streptococcus; and also 
some toxin-producing strains of E. coli [32, 33].
3.3.3.6. Anesthesia and late complications
In addition to the complications of anesthesia or intravenous sedation, D&C may result in 
adhesions (Asherman’s syndrome). Intrauterine adhesion increases the risks of future ectopic 
pregnancy, miscarriage, or abnormal placentation (placenta previa and accreta) [34]. The risk 
of preterm birth after induced abortion is higher than that in a first pregnancy or after a previ-
ous live birth. Surgical but not medical abortion appears to be associated with an increased risk 
of spontaneous preterm birth [34]. These data warrant caution in the use of surgical uterine 
evacuation and should encourage safer surgical techniques as well as medical methods [34, 35].
3.4. Medical termination
Whenever surgical abortion is difficult or unacceptable, medication abortion should be consid-
ered. Mifepristone (RU 486) is a 19-norsteroid that specifically blocks receptors for progesterone 
and glucosteroids. Acting as a competitive inhibitor of the progesterone receptor, mifepristone 
is used as a pretreatment 24–48 h before inducing first-trimester abortion with a prostaglan-
din analog. Misoprostol, a synthetic prostaglandin E1 analog, has been proven effective for 
pregnancy termination at various gestational ages, cervical ripening, labor induction in term 
pregnancies, and incomplete abortion treatment. The combination of a mifepristone and a pros-
taglandin derivative was the most effective regimen for medical pregnancy termination [36].
Mifepristone is approved by FDA for medical abortion up to 49 days of estimated gestational 
age. However, mifepristone is commonly used in combination with vaginal or buccal miso-
prostol at higher gestational ages based on studies demonstrating safety and efficacy up to 
9 weeks [36]. Recent data support the use of mifepristone for outpatient abortion through 
70 days of gestation, since similar safety and effectiveness as those used at 63 days of gesta-
tion have been demonstrated [37]. Mifepristone and misoprostol may also be used from 10 to 
13 weeks [39]. This will require a setting whereby patients’ condition can be monitored and 
a repeated dose of misoprostol administered given the potential risk of excessive bleeding at 
this later gestational age. Depending on the local regulations, the candidate setting could be a 
labor and delivery unit or gynecology inpatient department [37–39].
The combined use of mifepristone and misoprostol for second-trimester termination has a 
shorter induction time and lower misoprostol dose compared with misoprostol alone [39]. 
Both sublingual and vaginal routes of misoprostol administration resulted in a shorter abor-
tion duration than the oral route [40]. The differences in duration or side effects between 
sublingual and vaginal routes of misoprostol administration were not significant. However, 
sublingual administration may be preferred by patients over vaginal administration due to 
ease of use [39].
It is effective and feasible to prevent unintended pregnancy with low-dose mifepristone com-
bined with misoprostol before expected menstruation or menstruation regulation after missed 
period. The success rate of abortion for mifepristone-misoprostol regimen is 95–98%. [41], 
while 78–90% for misoprostol only [42]. Despite highly restrictive abortion laws in LAC, access 
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to safer abortion increased. Significant barriers still exist; thus, it is necessary to enhance the 
use of modern contraceptive and safer abortion methods among women in the region [43, 44].
4. Postabortion care
Postabortion care is part of the reproductive health care in women after induced abortions. 
Extreme urgent demand in LMICs is understandable given that, in most of them, induced 
abortion is either completely illegal or legal but with limited access by women who need it. In 
such settings, the only option for women wishing to end their pregnancies is to procure clan-
destine, usually unsafe abortions—with substantial negative consequences for themselves, 
their families, and their societies [44]. It has been shown that comprehensive family planning 
would reduce unintended pregnancies and therefore the incidence of unsafe abortions [45].
All women seeking an abortion should be offered a contraceptive method. Long-acting 
reversible contraceptives, such as the intrauterine device (IUD), the progestin implant or 
the progestin injection (depot medroxyprogesterone acetate or DMPA), have been found to 
statistically significantly decrease abortion incidence [46]. IUDs placed immediately after an 
abortion lower the rate of repeat abortions from 34.6 per 1000 woman-years to 91.3 per 1000 
woman-years in controls [47]. Immediate postabortal IUDs are safe and effective, although 
they have a slightly higher expulsion, ranging from 3 to 5% immediately after an abortion 
compared with 0–2.7% in interval groups [48]. However, at 6 months postabortion, IUD use is 
higher following immediate insertion compared to delayed insertion [49]. Women interested 
in progestin or combined hormonal contraceptives can be given a prescription before leaving 
the clinic to be started immediately after the procedure [50].
5. Conclusions
Surgical methods for abortion are effective and more cost-effective than medical manage-
ment, particularly in LMICs where access to medical interventions might be limited. They are 
associated with fewer side effects such as pain and bleeding—a critical advantage in LMICs, 
where health facilities might be distant and transportation difficult.
Access to VA and D&C should be increased by training more health workers and invest-
ing in surgical equipment in secondary health-care settings. Although surgical management 
of incomplete abortion predominates where such services are available in LMICs, increased 
access should be a priority to improve postabortion care and reduce abortion-related mor-
bidity and mortality. Medical abortion is an effective, safe, private pregnancy termination. It 
should be provided as a personal choice for use.
Supporting patients to identify high-quality decision aids and facilitating nonspecialist devel-
opers’ adoption of best practices are needed. Increased investment in family planning will 
help satisfy the large unmet need for contraception by reducing the number of unintended 
pregnancies and dramatically lower maternal mortality and morbidity as well as the number 
of unsafe abortions.
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